Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab

Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Biol Chem
Main Authors: Davies, Anna M., Allan, Elizabeth G., Keeble, Anthony H., Delgado, Jean, Cossins, Benjamin P., Mitropoulou, Alkistis N., Pang, Marie O. Y., Ceska, Tom, Beavil, Andrew J., Craggs, Graham, Westwood, Marta, Henry, Alistair J., McDonnell, James M., Sutton, Brian J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Biochemistry and Molecular Biology 2017
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5473249/
https://ncbi.nlm.nih.gov/pubmed/28438838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M117.776476
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados